About Us
Company History
The Team
Executive Management
Board of Directors
Scientific Advisory Board
Partners
|
Product
|
Science
Scientific Overview
Epitope-based Approach
Scientific Publications
|
Influenza
The Flu Virus
The Flu and Global Health
Useful Links
|
News & Media
Events & Presentations
BiondVax in the News
Press Kit
|
Investor Relations
Stock Information
Ownership Structure
Financial Reports
Regulatory Filings
Analysts
|
Careers
|
Contact Us
Home
>> News & Media
News & Media
News & Media
►
Press Releases
Events and
Presentations
BiondVax in the News
Press Kit
Press Releases
2012
10 December 2012
BiondVax's Universal Influenza Vaccine M-001 Significantly Enhances the Efficacy of the Human Pandemic H5N1 Bird Flu Vaccine
18 October 2012
BiondVax and MonoSol to Collaborate on Developing Oral Delivery for Universal Flu Vaccine M-001
18 October 2012
BiondVax Passes European QP GMP Audit - The Green Light to Advance Clinical Development of its Universal Flu Vaccine in the EU
2 May 2012
BiondVax's Progress is Focus of Nature News Article
27 Feb 2012
BiondVax Announces Universal Flu Vaccine Improves Existing Flu Vaccines in Elderly in Second Phase II Trial
2011
29 August 2011
BiondVax Announces Receipt of IRB Ethics Committee Approvals for Initiation of Second Phase II Clinical Trial for Universal Flu Vaccine
16 June 2011
BiondVax Announces Positive Phase IIa Results for Universal Flu Vaccine
31 May 2011
BiondVax to Present Phase IIa Results at 2011 BIO International Convention
